+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Syphilis Testing Market Size, Share & Industry Trends Analysis Report By Type, By Location of Testing testing), By Regional Outlook and Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 140 Pages
  • May 2022
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5615697
The Global Syphilis Testing Market size is expected to reach $1.5 billion by 2028, rising at a market growth of 5.6% CAGR during the forecast period.



Syphilis is a bacteria-induced sexually transmitted disease (STDs) caused by Treponema pallidum. The very first two stages are the most contagious. The early phase of syphilis is the concealed, or latent, stage, during which the patient is unaffected. The disease is still present, but there are no noticeable symptoms. The second stage, tertiary syphilis, is the most dangerous to one's health.

Syphilis occurs in stages, each with its own set of symptoms. The stages, however, might intersect, and indications do not usually appear in the same order. The user could have syphilis for years without noticing any signs. A tiny sore called a chancre (SHANG-kur) is the first indication of syphilis. The sore occurs where the germs entered the body for the first time. While the majority of persons with syphilis get only one chancre, some develop numerously. The chancre usually emerges three weeks after exposure. Since the chancre is usually painless and can be concealed within the vaginal or rectum, many persons with syphilis are unaware of it. Within three to six weeks, the chancre is expected to heal on its own.

Treponema pallidum subspecies pallidum is a Gram-negative, highly mobile bacterium with a spiral structure. Yaws (subspecies pertenue), bejel (subspecies carateum), and pinta (subspecies carateum) are three more human diseases caused by the Treponema pallidum subspecies. They do not cause neurological illness, unlike subspecies pallidum. It cannot survive without a host for more than a few days. This is because its tiny genome (1.14Mbp) lacks the metabolic pathways required to produce the majority of its macronutrients. It takes more than 30 hours to double in size. The bacterium is notorious for its capability to avoid the immune system along with its invasiveness.

COVID-19 Impact Analysis


The overall impact of COVID-19 on the syphilis testing market is negative, owing to a decrease in the number of patient visits to hospitals and clinics for testing, as a result of the suspension of various elective surgeries and outpatient visits, which reduced the market's demand for syphilis tests. The COVID-19 pandemic is a public-health disaster that has harmed the STD testing industry. Before the pandemic, the number of sexually transmitted infection cases was significant, but after the pandemic, STD testing cases decreased. During the early months of the COVID-19 pandemic, testing reports of sexually transmitted diseases were down due to challenges in health care and sexually transmitted infection testing services.

Market Growth Factors:


Rising public awareness about syphilis treatment


Utilizing the social media platforms and the various campaigns by the NGO and various authorities are making people aware about the Syphilis testing market. During STD Awareness Week, which occurs during the second full week of April, people are encouraged to become aware of STDs and how they impact their lives. The goal is to reduce stigma, fear, and discrimination associated with STDs, as well as to make sure that people have the tools and knowledge they need to prevent, detect, and treat STDs. Many governments in developed and developing countries are attempting to raise public awareness about the necessity of early STD testing.

Increasing government funding or investments on STD testing


Several government agencies are increasing their investments in the development of quick and accurate STD testing since it aids in the control of syphilis cases by administering the appropriate treatments at the appropriate time. Patients with STDs have a much higher death risk because they are not tested with the appropriate measures at the appropriate time, making their condition more fragile and harder to cure. The government as well as other healthcare organizations have developed different initiatives to raise public awareness of STDs.

Marketing Restraining Factor:


Impact of social taboos and stigmas


The extensive efforts to identify basic interventions that can help to reduce risky sexual behavior, altering one's behavior remains challenging. According to surveys, it is vital to focus on well-defined communities, interact extensively with specified target audiences, and incorporate them in the designing, implementation, and evaluation processes. There are still several stigmas associated with STDs that prevent people from being checked. Many STDs are thought to be stigmatized in society. In other words, persons who are infected with STDs are judged or condemned. Other diseases may also be associated with societal stigma.

Type Outlook


Based on Type, the market is segmented into Primary & Secondary Syphilis and Others. The Primary & Secondary Syphilis acquired the largest revenue share in the syphilis testing market in 2021. It is due to the increasing prevalence of syphilis infections as well as the availability of screening tests like automated treponemal tests (TTs), such as enzyme immune assays (EIAs) for primary syphilis and the RPR card as well as serological tests like VDRLs and USRs for secondary syphilis.

Location of Testing Outlook


Based on Location of Testing, the market is segmented into Laboratory testing and Point of care (POC) testing. The Point of care (POC) testing segment registered a significant revenue share in the syphilis testing market in 2021. It is due to the majority of syphilis POC tests can be used as screening tests because they identify antibodies directed to Treponema pallidum (TP), the syphilis causative agent. People who have not got professional laboratory training can also undertake POC testing. It includes the use of nurses, doctors, paramedics, and patient testing. Malaria antigen testing, blood glucose monitoring, pregnancy tests, urinalysis, and other types of near-patient testing are only a few examples.

Regional Outlook


Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. The North America region garnered the highest revenue share in the syphilis testing market in 2021. Due to the higher adoption rates for technologically advanced screening test methods, active efforts from governments and private organizations, and growing awareness of syphilis infections all contribute to the market's growth in North America. In addition, increased syphilis cases due to men having sex with men (MSM) and the introduction of mandated screening tests for all pregnant women in these regions is expected to fuel the expansion of the syphilis testing market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid), and F. Hoffmann-La Roche Ltd.

Scope of the Study


Market Segments Covered in the Report:


By Type

  • Primary & Secondary Syphilis
  • Others

By Location of Testing

  • Laboratory testing
  • Point of care (POC) testing

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • Siemens Healthineers AG
  • Abbott Laboratories
  • DiaSorin S.p.A. (Luminex Corporation)
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Frequently Asked Questions about the Global Syphilis Testing Market

What is the estimated value of the Global Syphilis Testing Market?

The Global Syphilis Testing Market was estimated to be valued at $1012 Million in 2021.

What is the growth rate of the Global Syphilis Testing Market?

The growth rate of the Global Syphilis Testing Market is 5.6%, with an estimated value of $1469 Million by 2028.

What is the forecasted size of the Global Syphilis Testing Market?

The Global Syphilis Testing Market is estimated to be worth $1469 Million by 2028.

Who are the key companies in the Global Syphilis Testing Market?

Key companies in the Global Syphilis Testing Market include Siemens Healthineers AG, Abbott Laboratories, DiaSorin S.p.A. (Luminex Corporation), Hologic, Inc., Bio, Rad Laboratories, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Danaher Corporation (Cepheid) and F. Hoffmann.

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Syphilis Testing Market, by Type
1.4.2 Global Syphilis Testing Market, by Location of Testing
1.4.3 Global Syphilis Testing Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Syphilis Testing Market by Type
3.1 Global Primary & Secondary Syphilis Market by Region
3.2 Global Others Market by Region
Chapter 4. Global Syphilis Testing Market by Location of Testing
4.1 Global Laboratory testing Market by Region
4.2 Global Point of care (POC) testing Market by Region
Chapter 5. Global Syphilis Testing Market by Region
5.1 North America Syphilis Testing Market
5.1.1 North America Syphilis Testing Market by Type
5.1.1.1 North America Primary & Secondary Syphilis Market by Country
5.1.1.2 North America Others Market by Country
5.1.2 North America Syphilis Testing Market by Location of Testing
5.1.2.1 North America Laboratory testing Market by Country
5.1.2.2 North America Point of care (POC) testing Market by Country
5.1.3 North America Syphilis Testing Market by Country
5.1.3.1 US Syphilis Testing Market
5.1.3.1.1 US Syphilis Testing Market by Type
5.1.3.1.2 US Syphilis Testing Market by Location of Testing
5.1.3.2 Canada Syphilis Testing Market
5.1.3.2.1 Canada Syphilis Testing Market by Type
5.1.3.2.2 Canada Syphilis Testing Market by Location of Testing
5.1.3.3 Mexico Syphilis Testing Market
5.1.3.3.1 Mexico Syphilis Testing Market by Type
5.1.3.3.2 Mexico Syphilis Testing Market by Location of Testing
5.1.3.4 Rest of North America Syphilis Testing Market
5.1.3.4.1 Rest of North America Syphilis Testing Market by Type
5.1.3.4.2 Rest of North America Syphilis Testing Market by Location of Testing
5.2 Europe Syphilis Testing Market
5.2.1 Europe Syphilis Testing Market by Type
5.2.1.1 Europe Primary & Secondary Syphilis Market by Country
5.2.1.2 Europe Others Market by Country
5.2.2 Europe Syphilis Testing Market by Location of Testing
5.2.2.1 Europe Laboratory testing Market by Country
5.2.2.2 Europe Point of care (POC) testing Market by Country
5.2.3 Europe Syphilis Testing Market by Country
5.2.3.1 Germany Syphilis Testing Market
5.2.3.1.1 Germany Syphilis Testing Market by Type
5.2.3.1.2 Germany Syphilis Testing Market by Location of Testing
5.2.3.2 UK Syphilis Testing Market
5.2.3.2.1 UK Syphilis Testing Market by Type
5.2.3.2.2 UK Syphilis Testing Market by Location of Testing
5.2.3.3 France Syphilis Testing Market
5.2.3.3.1 France Syphilis Testing Market by Type
5.2.3.3.2 France Syphilis Testing Market by Location of Testing
5.2.3.4 Russia Syphilis Testing Market
5.2.3.4.1 Russia Syphilis Testing Market by Type
5.2.3.4.2 Russia Syphilis Testing Market by Location of Testing
5.2.3.5 Spain Syphilis Testing Market
5.2.3.5.1 Spain Syphilis Testing Market by Type
5.2.3.5.2 Spain Syphilis Testing Market by Location of Testing
5.2.3.6 Italy Syphilis Testing Market
5.2.3.6.1 Italy Syphilis Testing Market by Type
5.2.3.6.2 Italy Syphilis Testing Market by Location of Testing
5.2.3.7 Rest of Europe Syphilis Testing Market
5.2.3.7.1 Rest of Europe Syphilis Testing Market by Type
5.2.3.7.2 Rest of Europe Syphilis Testing Market by Location of Testing
5.3 Asia Pacific Syphilis Testing Market
5.3.1 Asia Pacific Syphilis Testing Market by Type
5.3.1.1 Asia Pacific Primary & Secondary Syphilis Market by Country
5.3.1.2 Asia Pacific Others Market by Country
5.3.2 Asia Pacific Syphilis Testing Market by Location of Testing
5.3.2.1 Asia Pacific Laboratory testing Market by Country
5.3.2.2 Asia Pacific Point of care (POC) testing Market by Country
5.3.3 Asia Pacific Syphilis Testing Market by Country
5.3.3.1 China Syphilis Testing Market
5.3.3.1.1 China Syphilis Testing Market by Type
5.3.3.1.2 China Syphilis Testing Market by Location of Testing
5.3.3.2 Japan Syphilis Testing Market
5.3.3.2.1 Japan Syphilis Testing Market by Type
5.3.3.2.2 Japan Syphilis Testing Market by Location of Testing
5.3.3.3 India Syphilis Testing Market
5.3.3.3.1 India Syphilis Testing Market by Type
5.3.3.3.2 India Syphilis Testing Market by Location of Testing
5.3.3.4 South Korea Syphilis Testing Market
5.3.3.4.1 South Korea Syphilis Testing Market by Type
5.3.3.4.2 South Korea Syphilis Testing Market by Location of Testing
5.3.3.5 Singapore Syphilis Testing Market
5.3.3.5.1 Singapore Syphilis Testing Market by Type
5.3.3.5.2 Singapore Syphilis Testing Market by Location of Testing
5.3.3.6 Malaysia Syphilis Testing Market
5.3.3.6.1 Malaysia Syphilis Testing Market by Type
5.3.3.6.2 Malaysia Syphilis Testing Market by Location of Testing
5.3.3.7 Rest of Asia Pacific Syphilis Testing Market
5.3.3.7.1 Rest of Asia Pacific Syphilis Testing Market by Type
5.3.3.7.2 Rest of Asia Pacific Syphilis Testing Market by Location of Testing
5.4 LAMEA Syphilis Testing Market
5.4.1 LAMEA Syphilis Testing Market by Type
5.4.1.1 LAMEA Primary & Secondary Syphilis Market by Country
5.4.1.2 LAMEA Others Market by Country
5.4.2 LAMEA Syphilis Testing Market by Location of Testing
5.4.2.1 LAMEA Laboratory testing Market by Country
5.4.2.2 LAMEA Point of care (POC) testing Market by Country
5.4.3 LAMEA Syphilis Testing Market by Country
5.4.3.1 Brazil Syphilis Testing Market
5.4.3.1.1 Brazil Syphilis Testing Market by Type
5.4.3.1.2 Brazil Syphilis Testing Market by Location of Testing
5.4.3.2 Argentina Syphilis Testing Market
5.4.3.2.1 Argentina Syphilis Testing Market by Type
5.4.3.2.2 Argentina Syphilis Testing Market by Location of Testing
5.4.3.3 UAE Syphilis Testing Market
5.4.3.3.1 UAE Syphilis Testing Market by Type
5.4.3.3.2 UAE Syphilis Testing Market by Location of Testing
5.4.3.4 Saudi Arabia Syphilis Testing Market
5.4.3.4.1 Saudi Arabia Syphilis Testing Market by Type
5.4.3.4.2 Saudi Arabia Syphilis Testing Market by Location of Testing
5.4.3.5 South Africa Syphilis Testing Market
5.4.3.5.1 South Africa Syphilis Testing Market by Type
5.4.3.5.2 South Africa Syphilis Testing Market by Location of Testing
5.4.3.6 Nigeria Syphilis Testing Market
5.4.3.6.1 Nigeria Syphilis Testing Market by Type
5.4.3.6.2 Nigeria Syphilis Testing Market by Location of Testing
5.4.3.7 Rest of LAMEA Syphilis Testing Market
5.4.3.7.1 Rest of LAMEA Syphilis Testing Market by Type
5.4.3.7.2 Rest of LAMEA Syphilis Testing Market by Location of Testing
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Danaher Corporation (Cepheid)
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 Becton, Dickinson and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Thermo Fisher Scientific, Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expense
6.5 Bio-Rad laboratories, Inc.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expenses
6.6 Hologic, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent Strategies and Developments:
6.6.5.1 Approvals and Trials:
6.7 DiaSorin S.p.A. (Luminex Corporation)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Abbott Laboratories
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent Strategies and Developments:
6.8.5.1 Approvals and Trials:
6.9 Siemens Healthineers AG (Siemens AG)
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses

Companies Mentioned

  • Siemens Healthineers AG
  • Abbott Laboratories
  • DiaSorin S.p.A. (Luminex Corporation)
  • Hologic, Inc.
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson and Company
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd.

Methodology

Loading
LOADING...